Pedram Navid-Azarbaijani

Statistics

Publications

Citations

200

H-Index

Active since

2016

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Pedram Navid-Azarbaijani is an author at Memorial Sloan Kettering Cancer Center specializing in immunotherapy for skin cancer, checkpoint inhibitor therapy, and pharmacotherapy.

Publications per year

2016–2017

Publications

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Alexander N. Shoushtari, Claire F. Friedman, Pedram Navid-Azarbaijani et al. · JAMA Oncology · 2017 · 163 citations

Medicine, Oncology, Pharmacotherapy +17

Activation of the Chicken Anemia Virus Apoptin Protein by Chk1/2 Phosphorylation Is Required for Apoptotic Activity and Efficient Viral Replication

Thomas J. Kucharski, Timothy F. Ng, David Sharon et al. · Journal of Virology · 2016 · 24 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).

Alexander N. Shoushtari, Pedram Navid-Azarbaijani, Claire F. Friedman et al. · Journal of Clinical Oncology · 2016 · 13 citations

Pharmacy, Oncology, Pharmacotherapy +17

1–3 of 3